{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:03:06Z","timestamp":1795136586033,"version":"4.10.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore efficacy and safety of CD19-directed Chimeric Antigen Receptor (CAR) T cell therapy in a patient with Jo1-Antisynthetase-syndrome refractory to multiple immunosuppressants, including anti-CD38 therapy, and review published cases on CAR T cell therapy in idiopathic inflammatory myopathies (IIM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Following lymphodepletion, the patient received a single infusion of autologous CD19-directed CAR T cells. Clinical, serologic, and safety outcomes were monitored over 6\u2009months. A literature review analysed prior cases for patient characteristics, outcomes, and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CAR T cell therapy was well tolerated, with only low-grade cytokine release syndrome (CRS) and no neurotoxicity. Clinical assessments demonstrated significant and rapid improvement in muscle strength, arthritis, and pulmonary function, alongside normalization of muscle enzymes and inflammatory markers. Autoantibody levels remained unchanged. Transient skin alterations resolved with low-dose glucocorticoids. CAR T cells persisted for 3\u2009months, followed by B cell reconstitution without disease relapse. The patient remains in remission on low-dose prednisolone at 6\u2009months. Eight previously published cases of CAR T cell therapy in IIM consistently report significant improvement, with most patients stable off immunosuppressive therapy. Hypogammaglobulinemia was frequent, but no high-grade CRS, immune-effector-cell associated neurotoxicity syndrome (ICANS) or serious infections were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CD19-directed CAR T cell therapy shows promise in refractory IIM, offering sustained clinical improvement and a favourable safety profile. The nine reported cases collectively highlight the potential of CAR T cell therapy even in patients with insufficient response to B cell\/plasma-cell depleting therapies. Larger studies are needed to evaluate long-term efficacy, safety, and underlying mechanisms of CAR T cell therapy in refractory IIM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf190","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:49:24Z","timestamp":1745448564000},"page":"5101-5107","source":"Crossref","is-referenced-by-count":23,"title":["A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy\u2014case report and literature review"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3412-6838","authenticated-orcid":false,"given":"Isabell","family":"Haase","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]},{"name":"Clinic for Rheumatology and Immunology, Klinikum Bad Bramstedt , Bad Bramstedt,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3568-0710","authenticated-orcid":false,"given":"Johanna","family":"Richter","sequence":"additional","affiliation":[{"name":"Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-6728","authenticated-orcid":false,"given":"Marie-Therese","family":"Holzer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-7211","authenticated-orcid":false,"given":"Boris","family":"Fehse","sequence":"additional","affiliation":[{"name":"Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]},{"name":"Partner Site Hamburg, German Center for Child and Adolescent Health (DZKJ) , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-969X","authenticated-orcid":false,"given":"Nikolas","family":"Ruffer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Seibel","sequence":"additional","affiliation":[{"name":"Institute for Transfusion Medicine, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna C","family":"Berger","sequence":"additional","affiliation":[{"name":"Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[{"name":"Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3569-2576","authenticated-orcid":false,"given":"Dominic","family":"Borie","sequence":"additional","affiliation":[{"name":"Kyverna Therapeutics , Emeryville, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-1847","authenticated-orcid":false,"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-005X","authenticated-orcid":false,"given":"Ina","family":"K\u00f6tter","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]},{"name":"Clinic for Rheumatology and Immunology, Klinikum Bad Bramstedt , Bad Bramstedt,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0582-7790","authenticated-orcid":false,"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf , Hamburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025090315125883200_keaf190-B1","doi-asserted-by":"crossref","first-page":"104453","DOI":"10.1016\/j.nmd.2024.104453","article-title":"273rd ENMC International workshop: clinico-Sero-morphological classification of the Antisynthetase syndrome. Amsterdam, The Netherlands, 27-29 October 2023","volume":"45","author":"Stenzel","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"2025090315125883200_keaf190-B2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","article-title":"Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis","volume":"144","author":"Preu\u00dfe","year":"2022","journal-title":"Acta Neuropathol"},{"key":"2025090315125883200_keaf190-B3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090315125883200_keaf190-B4","doi-asserted-by":"crossref","first-page":"e309\u201311","DOI":"10.1093\/rheumatology\/kead668","article-title":"Comment on: rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Ruffer","year":"2024","journal-title":"Rheumatology"},{"key":"2025090315125883200_keaf190-B5","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","author":"Tur","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090315125883200_keaf190-B6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"2025090315125883200_keaf190-B7","doi-asserted-by":"crossref","first-page":"P57","DOI":"10.1186\/ar1578","article-title":"Expression of IL-18 in muscle tissue of patients with treatment-resistant idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2025090315125883200_keaf190-B8","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/rheumatology\/key222","article-title":"Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment","volume":"57","author":"Helmers","year":"2018","journal-title":"Rheumatology"},{"key":"2025090315125883200_keaf190-B9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"2025090315125883200_keaf190-B10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2021.07.017","article-title":"Cutaneous manifestations of chimeric antigen receptor T-cell therapy: an introduction for dermatologists","volume":"87","author":"Nusbaum","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025090315125883200_keaf190-B11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.4049\/jimmunol.1501902","article-title":"Involvement of NK Cells and NKp30 pathway in antisynthetase syndrome","volume":"197","author":"Hervier","year":"2016","journal-title":"J Immunol"},{"key":"2025090315125883200_keaf190-B12","doi-asserted-by":"crossref","first-page":"1035.e1","DOI":"10.1016\/j.jtct.2024.06.024","article-title":"Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system","volume":"30","author":"Storgard","year":"2024","journal-title":"Transplantat Cell Ther"},{"key":"2025090315125883200_keaf190-B13","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"2025090315125883200_keaf190-B14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"2025090315125883200_keaf190-B15","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"2025090315125883200_keaf190-B16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2025090315125883200_keaf190-B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"key":"2025090315125883200_keaf190-B18","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"2025090315125883200_keaf190-B19","first-page":"1560","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025090315125883200_keaf190-B20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"2025090315125883200_keaf190-B21","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125883200_keaf190-B22","doi-asserted-by":"crossref","first-page":"e2315990121","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025090315125883200_keaf190-B23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ymthe.2024.03.019","article-title":"CARs come to AID","volume":"32","author":"Ayuk","year":"2024","journal-title":"Mol Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf190\/62995601\/keaf190.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/5101\/62995601\/keaf190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/5101\/62995601\/keaf190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:13:07Z","timestamp":1756926787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/9\/5101\/8118840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,4,23]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf190","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,23]]}}}